Cladribine

Leustatin

Near Add Your Location

Sorting 6 by

Accepting patients

Cladribine, Cytarabine and Venetoclax for HR-MDS

A Phase II Study of Cladribine and Low Dose Cytarabine in Combination With Venetoclax, Alternating With Azacitidine and Venetoclax, in Patients With Higher-risk Myeloproliferative Chronic Myelomonocytic Leukemia or Higher-risk Myelodysplastic Syndromes With Excess Blasts
  • BCL-2 Inhibitor
  • Hypomethylating Agents (HMA)
  • Phase 2
  • Has results

Accepting patients

A Combination of Cladribine, Idarubicin, Cytarabine (CLIA) and Quizartinib for the Treatment of Patients With Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS))
  • Tyrosine Kinase (TK) Inhibitor
  • Phase 1/2

Accepting patients

Cytarabine Alternating with Decitabine

Phase II Study of Cladribine Plus Low Dose Cytarabine (LDAC) Induction Followed By Consolidation With Cladribine Plus LDAC Alternating With Decitabine in Patients With Untreated Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
  • Hypomethylating Agents (HMA)
  • Phase 2

Accepting patients

Chemotherapy Plus Venetoclax

Phase II Study of Cladribine Plus Idarubicin Plus Cytarabine (ARAC) in Patients With AML, HR MDS, or Myeloid Blast Phase of CML
  • BCL-2 Inhibitor
  • Kinase Inhibitor
  • Tyrosine Kinase (TK) Inhibitor
  • Phase 2

Accepting patients

Venetoclax as Part of Pre-Transplant Chemotherapy

Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS
  • BCL-2 Inhibitor
  • Phase 2

Accepting patients

Heart Protection w/Dexrazoxane During Chemotherapy

Cardioprotection With Dexrazoxane in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS), Myeloid Blast Phase of Chronic Myeloid Leukemia (CML), Ph+ AML, and Myeloid Blast Phase of Myeloproliferative Neoplasms
  • Chemotherapy
  • Phase 2